Clinical stage biotech firm Chemomab Therapeutics Ltd (Nasdaq: CMMB) announced on Tuesday that it has been granted new patents for CM-101, its pioneering monoclonal antibody addressing fibro-inflammatory diseases. The Brazilian and Israeli patents provide additional protections for CM-101's composition and use in liver-related fibrotic diseases, including primary sclerosing cholangitis (PSC).
CM-101 is currently in Phase 2 SPRING trial, with patient enrollment completed and topline data expected in mid-2024. The unique dual mechanism of action distinguishes CM-101 from other PSC treatments, showing promise in inhibiting fibrogenesis and impacting core PSC pathways.
The Brazilian patent, published on 2 January 2024, covers CM-101 broadly for fibrotic, inflammatory and autoimmune diseases, with a first-to-expire claim in 2035. The Israeli patent, granted on 2 February 2024, focuses on CM-101's use in hepatic diseases, extending protections until 2038. Combined with existing global patents, these additions are set to safeguard CM-101 across indications. CM-101, granted Orphan Drug designation in the US and the EU, has also received Fast Track designation from the FDA for PSC treatment in adults. The Phase 2 PSC trial aims to address a critical medical need in the absence of FDA-approved therapies for this potentially lethal condition.
Chemomab is advancing CM-101's development with positive results in Phase 2a liver fibrosis trials and investigator-initiated studies, positioning it as a potential treatment for various severe fibro-inflammatory diseases. The company anticipates significant market protection until 2038, with potential extensions upon market approval.
Cantargia reports positive safety and biomarker results in CAN10 phase 1 trial
NeuroSense Therapeutics pursues early commercialisation of ALS treatment in Canada
Ananda Developments PLC signs contract for Phase 1 PK study on MRX1
Lundbeck launches clinical trial for CD40L blocker Lu AG22515
Nektar Therapeutics showcases rezpegaldesleukin at EADV 2024
Priovant Therapeutics enrols first patients in brepocitinib CLARITY study
Kine Sciences reports first patient dosed in KINE-101 Phase 1b/2a clinical study
Johnson & Johnson receives approval from FDA for TREMFYA (guselkumab)
Pfizer names new Regional President for Middle East, Russia and Africa
GSK's Nucala approved in Japan for chronic rhinosinusitis with nasal polyps